Prenatal Carrier Testing for Fragile X: Counseling Issues and Challenges

Obstetrics and Gynecology Clinics of North America

Volumn 37, Issue 1, 2010, Pages 61-70

  Musci, Thomas J ^a   Moyer, Krista ^a,b  

^a San Francisco Perinatal Associates   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fragile X; Population screening; Prenatal carrier testing; Prenatal counseling

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; MESSENGER RNA;

ATAXIA; BEHAVIOR DISORDER; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FRAGILE X SYNDROME; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HEALTH CARE COST; HETEROZYGOTE DETECTION; HUMAN; PATHOGENESIS; PENETRANCE; PREMATURE OVARIAN FAILURE; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREMOR; TRINUCLEOTIDE REPEAT; VERTICAL TRANSMISSION;

AGED; AGED, 80 AND OVER; DNA-BINDING PROTEINS; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS; MALE; MIDDLE AGED; MUTATION; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 77953008247     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2010.03.004     Document Type: Review

References (39)

1. Cronister A., Teicher J., Rohlfs E.M., et al. Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis. Obstet Gynecol 2008, 111(3):596-601.
2. Pesso R., Berkenstadt M., Cuckle H., et al. Screening for fragile X syndrome in women of reproductive age. Prenat Diagn 2000, 20:611-614.
3. Hunter J.E., Epstein M.P., Tinker S.W., et al. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol 2008, 32(6):553-559.
4. Leehey M.A. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med 2009, 57(8):830-836.
5. McConkie-Rosell A., Abrams L., Finucane B., et al. Recommendations from multi disciplinary focus groups on cascade testing and genetic counseling for fragile X associated disorders. J Genet Couns 2007, 16:593-606.
6. Ennis S., Ward D., Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. Eur J Hum Genet 2006, 14(2):253-255.
7. Sherman S., Pletcher B.A., Driscoll D.A. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005, 7:584-587.
8. Gleicher N., Weghofer A., Barad D.H. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil Steril 2009, 91(5):1700-1706.
9. Bretherick K.L., Fluker M.R., Robinson W.P. FMR1 repeat sizes in the gray zone and high end of the normal range are associated with premature ovarian failure. Hum Genet 2005, 117:376-382.
10. Bodega B., Bione S., Dalpra L., et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod 2006, 21:952-957.
11. Bennett C.E., Conway G.S., Macpherson J.N., et al. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. Hum Reprod 2010, 25(5):1335-1338.
12. Hagerman R.J., Leehey M., Heinrichs W., et al. Intention tremor, parkinsonism and generalized brain atrophy in male carriers of fragile X. Neurology 2001, 57:127-130.
13. Hagerman P.J., Hagerman R.J. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004, 74:805-816.
14. Jacquemont S., Hagerman R.J., Leehey M.A., et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004, 291:460-469.
15. Coffey S.M., Cook K., Tartaglia N., et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008, 146A:1009-1016.
16. Kronquist K.E., Sherman S.L., Spector E.B. Clinical significance of tri-nucleotide repeats in fragile X testing: a clarification of American College of Medical Genetics guidelines. Genet Med 2008, 10(11):845-847.
17. Nolin S.L., Brown W.T., Glicksman A., et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet 2003, 72(2):454-464.
18. Parniewski P., Staczek P. Review: molecular mechanisms of TRS instability. Adv Exp Med Biol 2002, 516:1-25.
19. Jakupciak J.P., Wells R.D. Genetic instabilities of triplet repeat sequences by recombination. IUBMB Life 2000, 50(6):355-359.
20. Fernandez-Carvajal I., Lopez Posadas B., Pan R., et al. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn 2009, 11(4):306-310.
21. Tassone F., Beilina A., Carosi C., et al. Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 2007, 13(4):555-562.
22. Sullivan A.K., Marcus M., Epstein M.P., et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005, 20:402-412.
23. Brouwer J.R., Willemsen R., Oostra B.A. The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet 2009, 150B(6):782-798.
24. Spector E.B., Kronquist K.E. Fragile X: technical standards and guidelines. ACMG standards and guidelines for clinical genetics laboratories 2005. Available at:, Accessed February 5, 2010. http://www.acmg.net.
25. McConkie-Rosell A., Finucan B., Cronister A., et al. Genetic counseling for fragile X syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005, 14(4):246-270.
26. Cronister A., DiMaio M., Mahoney M.J., et al. Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet Med 2005, 7(4):246-250.
27. Fanos J.H., Spangner K.A., Musci T.J. Attitudes toward prenatal screening and testing for fragile X. Genet Med 2006, 8(2):129-133.
28. Song F.J., Barton P., Sleightholme V., et al. Screening for fragile X syndrome: a literature review and modeling study. Health Technol Assess 2003, 7:1-106.
29. Wilson J.M.G., Jungner G. Principles and practice of screening for disease 1968, World Health Organization, Geneva (Switzerland), p. 165.
30. Khoury M.J., McCabe L.L., McCabe E.R. Population screening in the age of genomic medicine. N Engl J Med 2003, 348:50-58.
31. Musci T. Screening for single gene genetic disease. Gynecol Obstet Invest 2005, 60:19-26.
32. Musci T., Caughey A.B. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening. Am J Obstet Gynecol 2005, 192(6):1905-1912. [discussion: 1912-5].
33. Lyon E., Yu P., Jama M., et al. A rapid PCR assay suitable for fragile X population screening [abstract 353]. In: Abstracts from the 16th Annual ACMG Annual Clinical Genetics Meeting Tampa (FL), March 25-29, 2009.
34. Strom C.M., Huang D., Li Y., et al. Development of a novel, accurate, automated, rapid, high-throughput technique suitable for population-based carrier screening for fragile X syndrome. Genet Med 2007, 9(4):199-207.
35. Dodds E.D., Tassone F., Hagerman P.J., et al. Polymerase chain reaction, nuclease digestion, and mass spectrometry based assay for the trinucleotide repeat status of the fragile X mental retardation 1 gene. Anal Chem 2009, 81(13):5533-5540.
36. Tercyak K.P., Bennett Johnson S., Roberts S.F., et al. Psychological response to prenatal genetic counseling and amniocentesis. Patient Educ Couns 2001, 43:73-84.
37. The American Society of Human Genetics Board of Directors, The American College of Medical Genetics Board of Directors. Drafted by a subcommittee of the ASHG Social Issues Committees. In: Wilfond BS, Pelias MZ, Knoppers BM, et al. Genetic testing in children and adolescents, points to consider: ethical legal and psychosocial implications of (ACMG/ASHG). Am J Hum Genet 1995, 57:1233-1241.
38. Wald N.J., Morris J.K. A new approach to antenatal screening for fragile X syndrome. Prenat Diagn 2003, 23:345-351.
39. Terracciano A., Pomponi M.G., Marino G.M., et al. Expansion to full mutation of a FMR1 intermediate allele over two generations. Eur J Hum Genet 2004, 12:333-336.